Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Spebrutinib"'
Publikováno v:
Heliyon, Vol 9, Iss 6, Pp e17058- (2023)
Spebrutinib is a new Bruton tyrosine kinase inhibitor developed by Avila Therapeutics and Celgene. Spebrutinib (SPB) is currently in phase Ib clinical trials for the treatment of lymphoma in the United States. Preliminary in-silico studies were first
Externí odkaz:
https://doaj.org/article/c844c6556d144888acaeafd44bc0ff4d
Publikováno v:
ImmunoTargets and Therapy, Vol Volume 10, Pp 333-342 (2021)
Laura C Arneson,1,* Kristen J Carroll,1,* Eric M Ruderman2 1Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Department of Medicine, Division of Rheumatology, Northwestern University Feinberg Sch
Externí odkaz:
https://doaj.org/article/72621ba3bca24812b7d1948272eb197b
Autor:
Peter H. Schafer, Alan J. Kivitz, Jianglin Ma, Shimon Korish, Donna Sutherland, Li Li, Ada Azaryan, Jolanta Kosek, Mary Adams, Lori Capone, Eun Mi Hur, Douglas R. Hough, Garth E. Ringheim
Publikováno v:
Rheumatology and Therapy, Vol 7, Iss 1, Pp 101-119 (2019)
Abstract Introduction Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways. This study evaluated spebrutinib pharmacology and mec
Externí odkaz:
https://doaj.org/article/39d20490cb6e49508dbe1a45ca6893e9
Publikováno v:
Royal Society Open Science, Vol 6, Iss 6 (2019)
Spebrutinib (SBT) is a Bruton's tyrosine kinase inhibitor. SBT is currently in phase II and phase I clinical trials for the management of rheumatoid arthritis and chronic lymphocytic leukaemia, respectively. We developed and validated a liquid chroma
Externí odkaz:
https://doaj.org/article/041b857bd5da4c60aff77ed496ee9958
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Satyavani Kaliamurthi, Chandrabose Selvaraj, Gilles H. Peslherbe, Gurudeeban Selvaraj, Dong-Qing Wei, Sanjeev Kumar Singh
Publikováno v:
International Journal of Molecular Sciences
Volume 22
Issue 13
International Journal of Molecular Sciences, Vol 22, Iss 7071, p 7071 (2021)
Volume 22
Issue 13
International Journal of Molecular Sciences, Vol 22, Iss 7071, p 7071 (2021)
Coronavirus disease (COVID)-19 is the leading global health threat to date caused by a severe acute respiratory syndrome coronavirus (SARS-CoV-2). Recent clinical trials reported that the use of Bruton’s tyrosine kinase (BTK) inhibitors to treat CO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9c1446eb24a0e0001bc0aeb0b0dd5e7
Autor:
Donatella Conconi, Marialuisa Lavitrano, Emanuela Grassilli, Maria Grazia Cerrito, Roberto Giovannoni, Sara Bonomo
Publikováno v:
Frontiers in Cell and Developmental Biology
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Frontiers in Cell and Developmental Biology, Vol 9 (2021)
Bruton’s tyrosine kinase (BTK) is a non-receptor intracellular kinase playing a key role in the proliferation and survival of normal and malignant B-lymphocytes. Its targeting by Ibrutinib, the first specific inhibitor, represented a turning point
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::133243402c67f8f83384bf57dd3ce960
Autor:
Vanina Rodriguez, Virginia Amador, Marta Leonor Rodríguez, Bola S. Hanna, Haniyeh Yazdanparast, Neus Villamor, Anna Vidal-Crespo, Martina Seiffert, Patricia Pérez-Galán, Peter Lichter, Laia Rosich, Elias Campo, Dolors Colomer, Mónica López-Guerra, Ariadna Giró, Marta Aymerich, Eriong Lee-Vergés, Julio Delgado
Publikováno v:
International Journal of Cancer. 144:2762-2773
The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been shown to be highly effective in patients with chronic lymphocytic leukemia (CLL) and is approved for CLL treatment. Unfortunately, resistance and intolerance to ibrutinib has been observ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e7f546200d6fa6233b2517b3e7689d2
https://doi.org/10.1002/ijc.32010
https://doi.org/10.1002/ijc.32010
Autor:
Dan Zhao, Zhihao Liu, Changyuan Wang, Yanxia Li, Kexin Liu, Xiaodong Ma, Jinyong Peng, Xiaohong Shu, Shan-Shan Huang, Zhen Li, Menghua Qu
Publikováno v:
European Journal of Medicinal Chemistry. 126:444-455
A new series of diphenylpyrimidine derivatives (DPPYs) bearing various aniline side chains at the C-2 position of pyrimidine core were synthesized as potent BTK inhibitors. Most of these inhibitors displayed improved activity against B leukemia cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd2692537eb5c59373ebd08b6b527c28
https://doi.org/10.1016/j.ejmech.2016.11.047
https://doi.org/10.1016/j.ejmech.2016.11.047
Autor:
Douglas R. Hough, Peter H. Schafer, Lori Capone, Jolanta Kosek, Mary Adams, Eun Mi Hur, Jianglin Ma, Li Li, S Korish, Ada Azaryan, Garth E. Ringheim, Donna Sutherland, Alan Kivitz
Publikováno v:
Rheumatology and Therapy
Rheumatology and Therapy, Vol 7, Iss 1, Pp 101-119 (2019)
Rheumatology and Therapy, Vol 7, Iss 1, Pp 101-119 (2019)
Introduction Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways. This study evaluated spebrutinib pharmacology and mechanism of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::840df98794e8caed1538859db21d1ce7
https://pubmed.ncbi.nlm.nih.gov/31721017
https://pubmed.ncbi.nlm.nih.gov/31721017